{"entity":{"id":"nct06690840","kind":"trial","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","aka":["AZALEA"],"tldr":"A phase 2 trial of atezolizumab, cyclophosphamide and vinorelbine in triple-negative breast cancer, run by European Institute of Oncology, now recruiting.","summary":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients is a phase 2, interventional study registered as NCT06690840 by European Institute of Oncology, with a registry enrolment figure of 45 participants, started 2025-03-06 and due to reach its primary completion in 2026-12-15. Interventions recorded: Atezolizumab in combination with Cyclophosphamide and Vinorelbine. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 \\[HER2\\], estrogen receptor \\[ER\\], and progesterone receptor \\[PR\\] expression) PD-L1+ (Immune Cell \\>1% using Ventana SP142 assay), not amenable to surgical therapy\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06690840","url":"https://clinicaltrials.gov/study/NCT06690840"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["atezolizumab","cyclophosphamide","vinorelbine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06690840","phase":"2","setting":"A Phase II Study of Atezolizumab, Vinorelbine and Weekly Cyclophosphamide as T-cell Activators in First Line Metastatic Triple Negative Breast Cancer Patients Pre-treated With Anti-PD-L1/PD-1","sponsor":"European Institute of Oncology","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06690840/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}